全文获取类型
收费全文 | 1622454篇 |
免费 | 132681篇 |
国内免费 | 2649篇 |
专业分类
耳鼻咽喉 | 21971篇 |
儿科学 | 53500篇 |
妇产科学 | 46672篇 |
基础医学 | 230309篇 |
口腔科学 | 47441篇 |
临床医学 | 143022篇 |
内科学 | 319155篇 |
皮肤病学 | 34510篇 |
神经病学 | 131938篇 |
特种医学 | 65715篇 |
外国民族医学 | 474篇 |
外科学 | 247047篇 |
综合类 | 39913篇 |
现状与发展 | 3篇 |
一般理论 | 565篇 |
预防医学 | 124433篇 |
眼科学 | 36786篇 |
药学 | 122709篇 |
3篇 | |
中国医学 | 3001篇 |
肿瘤学 | 88617篇 |
出版年
2018年 | 15627篇 |
2016年 | 13496篇 |
2015年 | 15788篇 |
2014年 | 21618篇 |
2013年 | 32577篇 |
2012年 | 44285篇 |
2011年 | 46511篇 |
2010年 | 27249篇 |
2009年 | 26059篇 |
2008年 | 44182篇 |
2007年 | 46397篇 |
2006年 | 47160篇 |
2005年 | 45633篇 |
2004年 | 44982篇 |
2003年 | 42938篇 |
2002年 | 41959篇 |
2001年 | 75852篇 |
2000年 | 78429篇 |
1999年 | 66529篇 |
1998年 | 17854篇 |
1997年 | 16423篇 |
1996年 | 16396篇 |
1995年 | 16086篇 |
1994年 | 15127篇 |
1993年 | 14263篇 |
1992年 | 55505篇 |
1991年 | 53839篇 |
1990年 | 52626篇 |
1989年 | 50889篇 |
1988年 | 47268篇 |
1987年 | 46615篇 |
1986年 | 44337篇 |
1985年 | 42904篇 |
1984年 | 32088篇 |
1983年 | 27608篇 |
1982年 | 16188篇 |
1981年 | 14488篇 |
1980年 | 13599篇 |
1979年 | 30498篇 |
1978年 | 21102篇 |
1977年 | 17791篇 |
1976年 | 16721篇 |
1975年 | 17600篇 |
1974年 | 21514篇 |
1973年 | 20707篇 |
1972年 | 18892篇 |
1971年 | 17789篇 |
1970年 | 16316篇 |
1969年 | 15289篇 |
1968年 | 13962篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
901.
902.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
903.
904.
905.
906.
907.
The intravenous injection into rabbits of suspensions of dead T. pallidum derived from rabbit testicular chancres regularly caused the appearance of Wassermann and flocculation antibodies in significantly increased titer. Control suspensions of cultured treponemes (Reiter strain) added to extracts of normal testes were ineffective. This suggests that the Wassermann and flocculation reagin elaborated during syphilitic infection may be an antibody to T. pallidum which happens to cross-react with alcoholic extracts of mammalian tissue. The antisera did not cause the agglutination of suspensions of pathogenic T. pallidum, living or dead, did not give specific complement fixation with those suspensions, and did not usually cause the living treponemata to lose their infectiousness. Animals immunized with such aqueous suspensions for as long as 4 months, or with organisms suspended in a water-in-oil emulsion, were not demonstrably resistant to infection. As few as ten living organisms inoculated intradermally into animals "immunized" with as many as 38 billion dead treponemata regularly produced typical darkfield positive infections; and two of five animals inoculated intratesticularly with ten organisms were also infected. The contradiction involved in the production of antibodies cross-reacting with a non-specific antigen, and the non-appearance of specific antibodies against the organism used as antigen, is discussed in the text. 相似文献
908.
909.
910.